Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Teleflex (TFX) to $146 from $214 and keeps an Equal Weight rating on the shares. The firm notes Q4 missed consensus and 2025 guidance came in well below consensus sales and EPS. Teleflex also announced the acquisition of Biotronik’s vascular business and the separation of its urology, acute care, and OEM businesses. Visibility on outlook is low, Wells adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TFX:
- Teleflex downgraded to Neutral from Overweight at Piper Sandler
- Teleflex downgraded to Market Perform from Outperform at Raymond James
- Teleflex Reports Steady Growth and Strategic Moves
- Teleflex Hold Rating: Uncertainty from Revenue Misses, Strategic Moves, and Growth Challenges
- Teleflex downgraded to Sector Perform from Outperform at RBC Capital